MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company’s proprietary vaccines. MabVax has filed three INDs in the last 14 months and received FDA authorization to proceed on all three. Two products are currently in phase I clinical trials. The first is a therapeutic product, MVT-5873, which is being evaluated as a single agent and in combination with a standard of care chemotherapy in a dose escalation safety trial in pancreatic cancer and other CA19-9 expressing cancers. The second product is MVT-2163, a PET imaging agent also being evaluated as a novel diagnostic agent in pancreatic cancer. The third product, MVT-1075, is a novel radioimmunotherapy product and the Company recently received authorization from FDA to proceed from FDA with our planned phase I clinical investigation. The Company anticipates that patient enrollment for the MVT-1075 study will be initiated in the second quarter 2017.